Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
2 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$161M | — | — | -$139M | — | $47M |
| 2024 | — | -$78M | — | — | -$80M | — | $38M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$61M | — | — | -$51M | — | $56M |
| Dec '25 | — | -$80M | — | — | -$47M | — | $47M |
| Sep '25 | — | -$29M | — | — | — | — | $64M |
| Jun '25 | — | -$30M | — | — | — | — | — |
| Mar '25 | — | -$22M | — | — | — | — | — |
| Dec '24 | — | -$21M | — | — | -$22M | — | $38M |
| Sep '24 | — | -$19M | — | — | — | — | — |
| Jun '24 | — | -$18M | — | — | — | — | — |
| Mar '24 | — | -$19M | — | — | — | — | — |
See the revenue and net-income charts above for Maplight Therapeutics, Inc.'s multi-year trend.
As of FY2025, Maplight Therapeutics, Inc. reported — of total debt against $47M of cash.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.